Cellectar Biosciences, Inc.
CLRBAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 5, 2026 | Roth Capital | Jonathan Aschoff | $11.00(+221%) | $3.42 | TheFly |
| Mar 28, 2024 | Oppenheimer | Jeff Jones | $12.00(+230%) | $3.63 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | upgrade | Hold →Buy | Mar 10, 2026 |
| Maxim Group | downgrade | Buy →Hold | May 14, 2025 |
| Oppenheimer | downgrade | Outperform →Perform | Dec 11, 2024 |
| Oppenheimer | maintain | Outperform | Nov 19, 2024 |
| Oppenheimer | maintain | Outperform | Mar 28, 2024 |
| Roth MKM | maintain | Buy | Mar 28, 2024 |
| Roth MKM | maintain | Buy | Mar 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 4, 2022 |
| Brookline Capital | maintain | Buy | Nov 25, 2020 |
| Oppenheimer | maintain | Outperform | Nov 25, 2020 |
| Maxim Group | maintain | Buy | Nov 25, 2020 |
| Roth Capital | maintain | Buy | Nov 25, 2020 |
| Oppenheimer | maintain | Outperform | Jul 1, 2020 |
| Maxim Group | maintain | Buy | Jun 23, 2020 |
| Roth Capital | maintain | Buy | Sep 13, 2019 |
| Brookline Capital | maintain | Buy | Jul 30, 2019 |
| H.C. Wainwright | maintain | Buy | May 2, 2019 |
| Ladenburg Thalmann | maintain | Buy | Dec 21, 2016 |
Earnings History
Next report: Mar 11, 2027 · EPS est. $-0.53| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.57 | $-0.52 | — | $12.0M |
| May 14, 2026 | $-1.33 | $-1.89 | — | $8.0M |
| Mar 4, 2026 | $-0.53 | $-1.19 | — | $12.8M |
| Nov 13, 2025 | $-1.41 | $-1.91 | — | — |
| Aug 14, 2025 | $-3.39 | $-3.60 | — | — |
| May 13, 2025 | $-3.90 | $-5.11 | — | — |
| Mar 13, 2025 | $-0.01 | $-0.38 | — | — |
| Nov 18, 2024 | $-16.52 | $-0.35 | — | — |
News
Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site activation advances, first patient dosing remains on track for 1Q 2027 and FDA filing for accelerated approval remains targeted for 1H27 FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical compan…
FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company will report financial results for the third quarter ended September 30, 2026, and provide a corporate update on November 10, 2026, at 8:30 a.m.
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Range of B-cell Malignancies FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today reported results from …
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months
Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program
Cellectar Biosciences, Inc. (NASDAQ: CLRB - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on